Dysarthria during irinotecan perfusion [1];Dysarthrie lors de l'administration d'irinotécan [1]

Revue de Medecine Interne

Volumn 23, Issue 11, 2002, Pages 950-951

  Ceccaldi, Bernard ^a   Kara, F ^b   Mommeja Marin, H ^b   Begue M ^b   Saint Blancard, P ^c   Le Marec, E ^b   Hauteville, D ^b  

^a University of Paris Descartes   (France)

^b SERVICE D ENDOCRINOLOGIE   (France)

^c PERCY MILITARY HOSPITAL   (France)

Author keywords

Adverse effect; Chemotherapy; Dysarthria; Irinotecan

Indexed keywords

IRINOTECAN;

ADENOCARCINOMA; ADULT; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DYSARTHRIA; FEMALE; FRANCE; HUMAN; LETTER; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DIAGNOSIS, DIFFERENTIAL; DYSARTHRIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 0036855951     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(02)00707-5     Document Type: Letter

References (8)

1. Chu G, Mantin R, Shen YM, Baskett G, Sussman H. Massive cisplatin overdose by accidental substitution for carboplatin. Cancer 1973;72:3707-14.
2. Pike MD, Arbus MH. Cisplatin overdosage. Am J Hosp Pharm 1992;49:1668.
3. Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996;52:606-23.
4. Sevilla-Garcia I, Rueba A, Alba E. Irinotecan-induced central nervous system toxicity: A case report. J Natl Cancer Inst 1999;91:647.
5. Blanney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, et al. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol 1998;41:464-8.
6. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999;17:1516-25.
7. Buckner J, Reid J, Schaaf L, Cha K, Wright R, Marks M, et al. A phase II trial of Irinotecan (CPT-11) in recurrent glioma. Proceedings ASCO abstr 2000(679A).
8. Gandia D, Abierges D, Armand JP, Chabot G, Da Costa L, De Forni M, et al. CPT-11 induced cholinergic effects in cancer patients. J Clin Oncol 1993;11:196-7.